oral glp-1 GLP-1 Peptide Serum, Oral Solution
Description
The orforglipron analysis looks at an oral GLP-1 agonist in development
The supplement is tested by NSF, an independent testing organization, for safety and dosage claims
The pilot program will also end in December 2027
On Monday morning, Novo Nordisk, the makers of the GLP-1 drug semaglutide (Ozempic and Wegovy), and Hims & Hers Health Inc
